The thyroid axis 'setpoints' are significantly altered after long-term suppressive LT4 therapy.

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Differentiated thyroid carcinoma (DTC) treatment often involves long-term suppressive levothyroxine (LT4) therapy.
• Monitoring thyroid-stimulating hormone (TSH) levels is crucial for managing DTC patients on LT4.
• Changes in thyroid axis setpoint and hormone metabolism can influence LT4 dosage requirements over time.

Purpose of the Study:

• To investigate alterations in the thyroid axis setpoint following long-term suppressive LT4 therapy in DTC patients.
• To determine the impact of these changes on the required LT4 dosage for maintaining TSH suppression.

Main Methods:

• Retrospective review of 99 differentiated thyroid cancer patients.
• Analysis of TSH, free T3 (FT3), and free T4 (FT4) levels, and LT4 dosage at two time points: within 2 years of initial treatment (time 1) and after ≥5 years of continuous LT4 therapy (time 2).
• Comparison of LT4 dosage per kilogram body weight required for TSH suppression between time 1 and time 2.

Main Results:

• Mean LT4 dosage/kg, TSH, FT3, and FT4 levels were significantly lower at time 2 compared to time 1.
• The FT3/FT4 ratio significantly decreased over time (p<0.001).
• The required LT4 dose for TSH suppression decreased by approximately 0.05 μg/kg/year, resulting in a 23.5% reduction after a median of 12.7 years.

Conclusions:

• Long-term TSH-suppressive therapy leads to a significant reduction in the LT4 dosage required per kilogram body weight for full TSH suppression.
• This dose reduction is partly independent of aging and attributed to changes in thyroid hormone metabolism and the thyroid axis setpoint.
• Findings suggest a need to re-evaluate and potentially adjust LT4 dosages in DTC patients undergoing long-term suppressive therapy.